Jan. 23 at 7:36 AM
Important news for Coherus (CHRS); it could be the next big squeeze.
It's trading at
$1.59, and after-hours trading has revealed that the prominent agency Oppenheimer recommends buying, with a price target of
$10.
"Oppenheimer initiates coverage of
$CHRS with an Outperform rating and a
$10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026."
Keep an eye on
$SXTP,
$BGL,
$ASTI, and
$NAMM today, which had a very bullish day yesterday. We'll see how they finish the week.
